14 April 2008



(“Sareum” or “the Company”)


Sareum Holdings plc (AIM: SAR), the specialist structure-based drug discovery business, is pleased to announce that it has agreed to place, through its broker, Dowgate Capital Stockbrokers Limited, 219,400,000 ordinary shares of 0.025p nominal value ("Ordinary Shares") at a price of 0.25p per share to raise £548,500 before expenses. The funds raised from this share issue will be used to provide additional working capital for the Company.

Following the issue of these shares, the Company's issued share capital will consist of 818,097,713 Ordinary Shares. The Company does not hold any ordinary shares in Treasury. Therefore the total number of ordinary shares with voting rights is now 818,097,713. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Services Authority's Disclosure and Transparency Rules.

Application has been made for the admission of 219,400,000 shares to trading on AIM with admission expected to take place on 18 April 2008.

Commenting on the announcement, Sareum's Chief Executive Officer, Dr Tim Mitchell said: "We are pleased to have been able to raise funds in difficult market conditions. This placing will provide valuable additional funds for the business."

For further information:

Sareum Holdings plc

01223 497700

Tim Mitchell, Chief Executive Officer


Buchanan Communications

020 7466 5000

Tim Anderson, Mary-Jane Johnson


Grant Thornton Corporate Finance

020 7383 5100

Philip Secrett, Colin Aaronson



Notes for editors:

About Sareum Holdings plc

Sareum Holdings plc is a structure-based drug discovery business headquartered in Cambridge, UK. The Company was formed in August 2003 to discover new drugs for the treatment of cancer.  Sareum’s unique approach aims to halve the time it takes to discover new drug candidates.

A structure-based approach to drug discovery relies on knowledge of the three-dimensional structure of the proteins that cause disease.  Once the structure is known, potential drugs are designed to ‘lock-in’ to the protein with the aim of reversing or arresting a disease’s progression.  Knowledge of the structure of the potential drugs and how they ‘lock-in’ to their target protein assists greatly in the development of high-quality drug candidates.  Determining structure is a complex task and requires leading-edge equipment and experienced staff.  Sareum’s approach to structure determination utilises its proprietary protein expression platform in order to produce multiple recombinant proteins that accelerate structure determination using x-ray crystallography.

Once the structure is determined, the Company’s innovative fragment screening platform is used to identify novel chemical templates designed to interact with the target protein.  Sareum then uses its high-throughput medicinal chemistry platform to rapidly optimise these molecules and develop the most promising into potential drug candidates.

Sareum aims to successfully deliver drug candidates for licensing to larger pharmaceutical companies at the pre-clinical or early clinical trials stage.  This is funded by provision of its specialist drug discovery capabilities to partners in the pharmaceutical and biotechnology industries.

Sareum joined the AIM market of the London Stock Exchange in October 2004 and trades under the symbol SAR.  For further information, please visit www.sareum.co.uk